恶性脑胶质瘤个体化化疗的研究进展

[13]Raval RR ,Lau K W ,Tran MG ,et al.Contrasting p r operties

of hypoxia 2inducible fact or 1(H I F 21)and H I F 22in von H i ppel 2L indau 2ass ociated renal cell carcinoma.Mol Cell B i 2ol.2005,25(13):567525686

[14]Nyhan MJ ,O ’Sullivan GC ,McKenna S L.Role of the VHL

(von H i ppel 2L indau )gene in renal cancer:a multifuncti onal tumour supp ress or.B i oche m Soc Trans.2008,36(Pt3):4722478.

[15]Hergovich A ,L iszt w an J ,Barry R ,el a1.Regulati on of m icr o 2

tubule stability by the von H i ppel 2L indau tumour supper 2ss or p r otein pVHL.Nat Cell B i ol.2003,5(1):64270.

[16]Tang N ,Mack F ,Haase VH ,et al.pVHL functi on is essen 2

tial for endothelial extracellular matrix depositi on.Mol Cell B i ol.2006,26(7):251922530.

[17]Hughes MD ,Kap llani E ,A lexander AE ,et al.H I F 22al pha

downregulati on in the absence of functi onal VHL is not suffi 2cient f or renal cell differentiati on.Cancer Cell I nt.

2007,

7:13.

[18]Hes FJ ,van der Luijt RB ,Janssen AL ,et al.Frequency of

Von H i ppel 2L indau ger m line mutati ons in classic and non 2classic Von H i ppel 2L indau disease identified by DNA sequen 2cing Southern bl ot analysis and multi p lex ligati on 2dependent p r obe a mp lificati on.Clin Genet.2007,72(2):1222129.

[19]Conway JE ,D ,Clatterbuck RE ,et al.He mangi oblast 2

omas of the central nervous syste m in von H i ppel 2L indau synd 2r ome and s poradic disease.Neur osurgery.2001,48

(1):55262.

[20]Knuds on AG J r,Str ong LC.Mutati on and cancer:neur obl 2

ast oma and pheochr omocyt oma.Am J Hum Genet.1972,

24:5142532.

[21]W izig mann 2Voos S ,B reier G ,R isau W ,et al.Up 2regula 2

ti on of vascular endothelial gr owth fact or and its recep t ors in von H i ppel 2L indau disease 2ass ociated and s poradic he mangi o 2blast 2omas.Cancer Res.1995,55(6):135821364.

[22]Kappas NC ,Zeng G ,Chappell JC ,et al.The VEGF recep 2

t or Flt 21s patially modulates Flk 21signaling and bl ood vessel branching.J Cell B i ol.2008,181(5):8472858.

[23]Finger PT,Chin K.Anti 2vascular endoth 2elial gr owth fact or

bevacizumab (avastin )f or radiati on reti 2nopathy.A rch Oph 2thal m ol.2007,125(6):7512756.

[24]Schuch G ,de W it M ,H ltje J ,et al.Case 2.He mangi obla 2

st omas:diagnosis of von H i ppel 2L indau disease and antiang 2i ogenic treat m ent with S U 5416.J Clin Oncol.

2005,23

(15):362423626.

[25]Hong S B ,Furihata M ,Baba M ,et al.Vascular defects and

liver damage by the acute inactivati on of the VHL gene during mouse e b I nvest,2006,86(7):6642

675.

收稿日期:2008-07-11;修回日期:2008-11-26

作者简介:王明(1983-),男,住院医师,硕士研究生,主要研究方向:神经胶质瘤的治疗

恶性脑胶质瘤个体化化疗的研究进展

王　明　综述 周永庆　徐庆生　审校

浙江大学医学院附属第一医院神经外科,浙江省杭州市　310003

摘　要:化疗是胶质瘤综合治疗的重要手段之一,但传统的化疗方案疗效不甚理想,原因主要是胶质瘤本身存在耐药性且有较强的个体化疗敏感性差异,故恶性脑胶质瘤需要个体化化疗。随着神经分子病理研究的发展,各种基因和蛋白水平上的个体化化疗成为研究的热点。本文对各种作用机制比较明确和以及仍处于研究阶段的恶性脑胶质瘤个体化疗作一综述。关键词:恶性脑胶质瘤;个体化;化疗

脑胶质瘤是起源于神经外胚层的肿瘤,是颅内最常见的恶性肿瘤,其中胶质母细胞瘤、间变性星型细胞瘤、间变性少突胶质细胞瘤和间变性少突星型细胞瘤都属于恶性脑胶质瘤的范畴,占了全部脑胶质瘤的半数以上。近年来研究发现,化疗对治疗恶

性胶质瘤具有一定的疗效,尤其随着替莫唑胺(te 2

mozolo m ide ,T MZ )等新型化疗药物的出现和新化疗方

案的探索,化疗疗效有了很大的提高,但不加选择的用药总有效率也只有50%,因此,如何在化疗前了解具体肿瘤对化疗的敏感性,制定出合理的个体化